Issue 19, May 2010
Dear Friends,

    A new study based on extensive analysis of JUPITER data confirms the use of 'hsCRP' indeed as a biomarker for CVD. The new Canadian guidelines on lipid management include this biomarker test, and the US is very much likely to follow suit. Incidentally Jothydev's Diabetes and Research Centre has been routinely performing hsCRP to accurately assess risk factors.

    Yet another study based on the same JUPITER data set confirms the benefits of statin therapy for female population as well, for which no statistically significant studies have been conducted so far. We also have a section, which articulates the necessity of simpler guidelines and tools for physicians to effectively diagnose and treat CVD risk patients. It is worrisome that the study report analysing the physicians' behaviour using almost a thousand doctors notices that the current guidelines are not strictly adhered by the vast majority and thus the targets are not adequately met.

    All the apprehensions based on the ACCORD study, which caused it to be stopped in between due to the supposedly high mortality rate, can be put to rest now. Intensive blood sugar management is extremely beneficial provided the patient responds to the treatment. A very recently published study concludes that Prolonged Metformin Usage reduces Breast Cancer Risk. You can read more details about both these studies in May 2010 Issue of GEMS.

    The diet section has an interesting presentation on how grapes are helpful in reducing risk factors for diabetes and heart attacks through antioxidants called phytochemicals.

    We hope you will be delighted to get detailed drug information on the much-awaited miraculous drug Liraglutide(VICTOZA) through the educational video presented by Dr.Jothydev Kesavadev. The drug update series continues in this issue of GEMS, for the benefit of practising physicians.

    If in case you are not interested in receiving this monthly newsletter, kindly reply with "delete gems" in the subject line to geeta@jothydev.net and a copy to gems@jothydev.net

Regards
JDC Diabetes Gems Team
Jothydev's Diabetes and Research Centre, Trivandrum, Kerala, INDIA
http://www.jothydev.net

   November 2008
   December 2008
   January 2009
   February 2009
  March 2009
  April 2009
  May 2009
  June 2009
  July 2009
  August 2009
  September 2009
  October 2009
  November 2009
  December 2009
  January 2010
  February 2010
  March 2010
April 2010



 
 
 
1.
hsCRP declared as a biomarker for CVD
The new Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease outline the potential use of inflammatory biomarker.........
2.
Rosuvastatin advantageous for fairer sex also
The role of lipid lowering through statins in primary prevention of cardiovascular events in women was unestablished so far because of few studies including enough women. ........
3.
Rising heart attacks: Physician's ignorance or negligence?
New study shows that, if doctors follow existing guidelines on cholesterol-lowering targets, they can prevent a greater number of heart attacks,s.........
4.
Intensive Blood Sugar Control proven the best for diabetes
Since decades, intensive blood glucose lowering had been proven to prevent eye, kidney and neuronal diseases in diabetes. Paradoxically, results from the ACCORD.........
5. Prolonged Metformin Usage reduces Breast Cancer Risk
The study, published in the journal Diabetes Care, reveals that metformin, the most commonly used drug for type 2 diabetes, may have anti-cancer effects...........
6
Grapes Reduce Risk Factors for Heart Disease and Diabetes
Findings presented on April 26 at the Experimental Biology convention in Anaheim, California by the Scientists at the University of Michigan..........
7
Diabetes Medicine Updates
A new diabetic drug of GLP-1 analogue class from Roche and Ipsen meets its end point. Patients who took 10 mg or 20 mg of the drug taspoglutide got better HbA1c test results than those who took placebo. The phase 3 study, called "T-emerge 3,"...........
8 JDC Updates
Jothydev's Diabetes and Research Centre has become the first ISO certified comprehensive out patient diabetes care centre in Kerala. Jothydev's Diabetes Centre apart from delivering state of the art diabetes care, also has been a pioneer since more than a decade in delivering ..........

The Newsletter team:
 Chief Editor
Dr. Jothydev Kesavadev
 Managing editor Sunitha Jothydev
 Sub Editor Dr. Arun Shankar
 Editor Neethu Annie Simon
Website counter Share/Bookmark